OLINCIGUAT

It’s only fair to share… OLINCIGUAT cas 1628732-62-6 Chemical Formula: C21H16F5N7O3 UNII-PD5F4ZXD21 Molecular Weight: 509.4 Olinciguat is a guanylate cyclase activator drug candidate. (2R)-3,3,3-trifluoro-2-{[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]- 5-(1,2-oxazol-3-yl)-1H-pyrazol- 3-yl}pyrimidin-4-yl)amino]methyl}-2-hydroxypropanamide Originator Ironwood Pharmaceuticals Class Antifibrotics; Cardiovascular therapies Mechanism of Action Soluble guanylyl cyclase agonists Orphan Drug StatusNo New Molecular EntityYes Highest Development Phases Phase II Gastrointestinal disorders; Sickle cell anaemia Phase I Cardiovascular disorders; …

OXCARBAZEPINE

It’s only fair to share… Oxcarbazepine KIN-493, GP-47680, Trileptal Molecular FormulaC15H12N2O2 Average mass252.268 Da 10-Oxo-10,11-dihydro-dibenzo[b,f]azepine-5-carboxylic acid amide 28721-07-5 [RN] 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo- UV Spectroscopy The UV absorption spectrum of carbamazepine in methanol shown in Fig. 1 was recorded using Shimadzu UV–vis Spectrometer 1601 PC. The compound exhibited maxima at 288 and 259 nm. Clarke reported the following: …

BICTEGRAVIR, NEW PATENT, WO 2018005328, CONCERT PHARMA

It’s only fair to share… BICTEGRAVIR, NEW PATENT, WO 2018005328, CONCERT PHARMA WO2018005328) DEUTERATED BICTEGRAVIR  CONCERT PHARMACEUTICALS, INC. TUNG, Roger, D.; (US) Concert CEO Roger Tung Novel deuterated forms of bictegravir is claimed.  Gilead Sciences is developing the integrase inhibitor bictegravir as an oral tablet for the treatment of HIV-1 infection. This invention relates to …

TRILACICLIB, G1T28

It’s only fair to share… Trilaciclib Molecular FormulaC24H30N8O Average mass446.548 Da G1T 28 CAS 1374743-00-6 2′-{[5-(4-Methyl-1-piperazinyl)-2-pyridinyl]amino}-7′,8′-dihydro-6’H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one G1T28, SHR 6390 Spiro[cyclohexane-1,9′(6’H)-pyrazino[1‘,2’:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one, 7′,8′-dihydro-2‘-[[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino]- 7′,8′-Dihydro-2′-[[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino]spiro[cyclohexane-1,9′(6’H)-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one 2′-[[5-(4-Methylpiperazin-1-yl)pyridin-2-yl]amino}-7′,8′-dihydro-6’H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one UNII:U6072DO9XG Reduction of Chemotherapy-Induced Myelosuppression Trilaciclib dihydrochloride 1977495-97-8 In phase II clinical development as a chemoprotectant at G1 Therapeutics for first- or second-line treatment in patients with metastatic triple negative breast cancer, in …

WO-2018001353, APREMILAST, NEW PATENT, ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD

It’s only fair to share… WO-2018001353, APREMILAST, NEW PATENT, ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD  (WO2018001353) METHOD FOR PREPARING APREMILAST ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD DU, Xiaoqiu; (CN). ZHOU, Lianchao; (CN). LIU, Jiegen; (CN) https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018001353&recNum=1&maxRec=&office=&prevFilter=&sortOption=&queryString=&tab=FullText EN)Method one: (S) -1- (3-ethoxy-4-methoxyphenyl) -2- (methylsulfonyl) ethylamine N-acetyl-L-leucine salt of formula II is reacted with 3-acetylaminophthalic anhydride of formula III …

(2R,3S,4R,5R)-1-(3-((5-(4-Fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-2,3,4,5,6-pentahydroxyhexan-1-one

It’s only fair to share… CAS 1672658-93-3 C24 H25 F O6 S, 460.52 D-Glucopyranose, 1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]- CAS 1809403-04-0 C24 H25 F O6 S, 460.52 D-Glucose, 1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]- WO2017/93949 (2R,3S,4R,5R)-1-(3-((5-(4-Fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-2,3,4,5,6-pentahydroxyhexan-1-one    12 From the FT-IR spectra of 12 contain a signal at 1674 cm–1, this signal is strongly indicative of a carbonyl ketone being present in 12 In 13C NMR and HMBC correlations spectra, the chemical shift at 199.75 ppm …

ELAGOLIX

It’s only fair to share… ELAGOLIX Molecular FormulaC32H30F5N3O5 Average mass631.590 Da NBI56418, ABT 620 UNII:5B2546MB5Z 4-({(1R)-2-[5-(2-Fluoro-3-methoxyphenyl)-3-[2-fluoro-6-(trifluoromethyl)benzyl]-4-methyl-2,6-dioxo-3,6-dihydro-1(2H)-pyrimidinyl]-1-phenylethyl}amino)butanoic acid 834153-87-6 FREE ACID SODIUM SALT  832720-36-2 Acide 4-({(1R)-2-[5-(2-fluoro-3-méthoxyphényl)-3-[2-fluoro-6-(trifluorométhyl)benzyl]-4-méthyl-2,6-dioxo-3,6-dihydro-1(2H)-pyrimidinyl]-1-phényléthyl}amino)butanoïque Butanoic acid, 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]- GNRH antagonist, Endometriosis Endometriosis PREREGISTERED Phase III Uterine leiomyoma WO2001055119A2, Inventors Yun-Fei Zhu, Chen Chen, Fabio C. Tucci, Zhiqiang Guo, Timothy D. Gross, Martin Rowbottom, R. Scott Struthers, Applicant Neurocrine Biosciences, Inc. WO 2005007165 PDT PATENT …

Empesertib , BAY 1161909

It’s only fair to share… Empesertib , BAY 1161909, Mps1-IN-5,  (-)-BAY-1161909 CAS 1443763-60-7 Chemical Formula: C29H26FN5O4S Molecular Weight: 559.6164 [a]D20 : -78.9° (in DMSO). WO 2014198647 UNII-02Y3Z2756M (αR)-4-Fluoro-N-[4-[2-[[2-methoxy-4-(methylsulfonyl)phenyl]amino][1,2,4]triazolo[1,5-a]pyridin-6-yl]phenyl]-α-methylbenzeneacetamide (R)-2-(4-fluorophenyl)-N-(4-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl)propanamide (2R)-2-(4-Fluorophenyl)-N-(4-(2-((4-(methanesulfonyl)-2-methoxyphenyl)amino)(1,2,4)triazolo(1,5-a)pyridin-6-yl)phenyl)propanamide Benzeneacetamide, 4-fluoro-N-(4-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)(1,2,4)triazolo(1,5-a)pyridin-6-yl)phenyl)-alpha-methyl-, (alphaR)- PHASE 1, BAYER, CANCER PRODUCT PATENT, WO2013087579, https://www.google.com/patents/WO2013087579A1   SYNTHESIS,  WO 2014198647 Analytical UPLC-MS was performed as follows: Method A: System: UPLC Acquity (Waters) with PDA Detector und Waters …

Biocon Launches KRABEVA® in India, A Biosimilar Bevacizumab for Treating Several Types of Cancer

It’s only fair to share… Biocon Launches KRABEVA® in India,  A Biosimilar Bevacizumab for Treating Several Types of Cancer On November 23, 2017, Biocon India’s premier Biopharmaceuticals Company announced that it has launched KRABEVA®, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers, …

Pexidartinib, New Patent, WO 2017215521, Crystal Pharmatech Co Ltd

It’s only fair to share… Pexidartinib, New Patent, WO, 2017215521, Crystal Pharmatech Co Ltd (WO2017215521) PLX3397 HYDROCHLORIDE CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017215521 CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD INVENTORS CHEN, Minhua; (CN). ZHANG, Yanfeng; (CN). ZOU, Po; (CN). ZHANG, Xiaoyu; (CN) Novel crystalline forms of PLX3397 hydrochloride (designated as Forms CS2 and …